platinum has been researched along with Squamous Cell Carcinoma of Head and Neck in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (29.41) | 24.3611 |
| 2020's | 24 (70.59) | 2.80 |
| Authors | Studies |
|---|---|
| Bossi, P; Capriotti, V; Ghidini, A; Lorini, L; Luciani, A; Petrelli, F; Trevisan, F | 1 |
| Blumenschein, G; Colevas, AD; Even, C; Fayette, J; Ferris, RL; Gillison, ML; Guigay, J; Haddad, R; Harrington, KJ; Iglesias Docampo, LC; Jayaprakash, V; Kasper, S; Kiyota, N; Licitra, L; Rordorf, T; Saba, NF; Tahara, M; Vokes, EE; Wei, L; Worden, F | 1 |
| Guo, Y; Liu, Y; Xia, Z; Xue, L; Zhang, Q | 1 |
| Fushimi, C; Hanyu, K; Ito, T; Kondo, T; Masubuchi, T; Matsuki, T; Miura, K; Okada, T; Okamoto, I; Omura, GO; Oridate, N; Sato, H; Tada, Y; Takahashi, H; Tokashiki, K; Tsukahara, K; Yamashita, T | 1 |
| Ho, AL | 1 |
| Bossi, P; Caldara, A; Canevari, S; Caponigro, F; Carenzo, A; Cavalieri, S; De Cecco, L; Denaro, N; Ferrari, D; Ferraù, F; Lenoci, D; Licitra, L; Miceli, R; Moretti, G; Moro, C; Pistore, F; Rinaldi, G; Rocca, MC; Secondino, S; Serafini, MS; Sponghini, A; Vaccher, E; Vecchio, S | 1 |
| Fujii, T; Fujimoto, Y; Gumuscu, B; Hanai, N; Hara, H; Matsumoto, K; Mitsugi, K; Nakayama, M; Nohata, N; Oridate, N; Shiga, K; Shimizu, Y; Swaby, RF; Tahara, M; Takahashi, K; Takahashi, M; Takahashi, S; Tanaka, K; Ueda, T; Yamaguchi, H; Yamazaki, T; Yasumatsu, R; Yokota, T; Yoshizaki, T | 1 |
| Biancalana, L; Ermini, ML; Frusca, V; Giannini, N; Gonnelli, A; Mapanao, AK; Marchetti, F; Santi, M; Sarogni, P; Voliani, V; Zamborlin, A | 1 |
| Biswas, S; Ghosh, B; Itoo, AM; Paul, M | 1 |
| Cabezas-Camarero, S; Cabrera-Martín, MN; Cerezo Druet, E; Iglesias-Moreno, MC; Merino-Menéndez, S; Pérez-Segura, P; Plaza-Hernández, JC; Sotelo, MJ | 1 |
| Campbell, SR; Geiger, JL; Koyfman, S; Lopetegui-Lia, N; Roof, L; Schwartzman, LM; Silver, N; Woody, NM; Yalamanchali, A; Yang, K; Yilmaz, E | 1 |
| Acharya, R; Anderson, JL; Delgoffe, GM; Ferris, RL; Harris, AL; Hsieh, RW; Li, J; Menk, AV; Nilsen, ML; Scheff, NN; Swartz, A; Zandberg, DP | 1 |
| Argiris, A; Bratland, Å; Chung, CH; Coutte, A; de Azevedo, S; Even, C; Fayette, J; Ferris, RL; Gillison, M; Grant, C; Grell, P; Haddad, R; Hansen, AR; Harrington, KJ; Khan, TA; Miller-Moslin, K; Redman, R; Roberts, M; Salas, S; Schenker, M; Soulières, D; Tahara, M; Walker, JWT; Wei, L | 1 |
| Bonomo, P; Borcoman, E; Cau, MC; Depenni, R; Ghi, MG; Ghiani, M; Le Tourneau, C; Leo, L; Messinger, D; Montesarchio, V; Ronzino, G; Salmio, S; Sbrana, A; Schulten, J | 1 |
| Borel, C; Chevalier, T; Collet, L; Daste, A; Fayette, J; Huguet, F; Richard, S; Saada-Bouzid, E; Salas, S; Tardy, M; Vienne, A | 1 |
| Ito, T; Okada, T; Okamoto, I; Tokashiki, K; Tsukahara, K; Yamashita, G | 1 |
| Ahn, MJ; Burtness, B; Cohen, EEW; Dinis, J; Ge, J; Harrington, KJ; Lerman, N; Licitra, L; Lin, J; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Tourneau, CL | 1 |
| Chang, PM; Chen, HL; Hsin, CH; Huang, WS; Lu, HJ; Peng, CY; Tseng, HC; Tseng, SW; Wu, MF; Yang, MH | 1 |
| Balermpas, P; Belka, C; Bergmann, T; Fietkau, R; Göhler, T; Große-Thie, C; Guntinas-Lichius, O; Hahn, D; Hautmann, MG; Hecht, M; Messinger, D; Orlowski, K; Reichert, D; Stenzel, KG; von der Grün, J; Welslau, M; Weniger, S; Wolber, P | 1 |
| Ding, H; Fang, Q; Tong, Y; Xin, W; Xu, G; Yang, G; Zheng, X | 1 |
| Fang, J; Feng, L; He, S; Lian, M; Ma, H; Tan, C; Wang, L; Wang, R; Yang, Y | 1 |
| Shi, YF; Xie, WZ | 1 |
| Dai, T; Liu, S; Lv, S; Pei, R; Shi, Y; Wu, B; Zhang, F | 1 |
| Fang, J; Wang, L; Wang, R | 1 |
| Black-Shinn, J; Boyd, M; Chirovsky, D; Joo, S; Nadler, E | 1 |
| Braakhuis, BJ; Brakenhoff, RH; Brink, A; Dalm, SU; Honeywell, RJ; Martens-de Kemp, SR; Peters, GJ; Wijnolts, FM | 1 |
| Chan, C; Colevas, AD; Jiang, W; Kong, C; Le, QT; Lee-Enriquez, N; Murphy, JD; Pinto, H; Tang, C; von Eyben, R | 1 |
| Alves, MP; Avezedo, I; de Mello, RA; Dinis, J; Gerós, S; Moreira, F | 1 |
| Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M | 1 |
| Fukuda, S; Furusawa, J; Hatakeyama, H; Homma, A; Iizuka, S; Kano, S; Mizumachi, T; Onimaru, R; Sakashita, T; Shirato, H; Tsuchiya, K; Yasuda, K | 1 |
| Caponigro, F; Clement, PM; Cohen, EE; Cong, XJ; Cupissol, D; de Castro, G; de Souza Viana, L; Del Campo, JM; Ehrnrooth, E; Fayette, J; Gauler, T; Grau, JJ; Guigay, J; Haddad, RI; Keilholz, U; Licitra, LF; Machiels, JP; Tahara, M; Vermorken, JB | 2 |
| Adkins, D; Aguilar, JL; Bryant, K; Chang, SC; Chen, E; Chin, S; Ernst, S; He, S; Lee, HJ; Misiukiewicz, K; Obasaju, CK; Soulières, D | 1 |
| Burhenne, J; Detering, JC; Dyckhoff, G; Haefeli, WE; Herold-Mende, C; Theile, D; Weiss, J | 1 |
3 review(s) available for platinum and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Comparison of platinum-based regimens in combination with radiotherapy for head and neck cancers: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Network Meta-Analysis; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Topics: Aged; Head and Neck Neoplasms; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Cost-Benefit Analysis; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Network Meta-Analysis; Nivolumab; Platinum; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Registries; Squamous Cell Carcinoma of Head and Neck; United States | 2021 |
7 trial(s) available for platinum and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Fluorouracil; Head and Neck Neoplasms; Humans; Japan; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Squamous Cell Carcinoma of Head and Neck | 2020 |
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck | 2014 |
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemistry, Pharmaceutical; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2016 |
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
24 other study(ies) available for platinum and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Topics: Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2022 |
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2022 |
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; ErbB Receptors; Head and Neck Neoplasms; Humans; Inflammation; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Hybrid nano-architectures loaded with metal complexes for the co-chemotherapy of head and neck carcinomas.
Topics: Carcinoma, Squamous Cell; Cisplatin; Coordination Complexes; Head and Neck Neoplasms; Humans; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Hypoxia alleviating platinum(IV)/chlorin e6-based combination chemotherapeutic-photodynamic nanomedicine for oropharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorophyllides; Head and Neck Neoplasms; Hypoxia; Mice; Mouth Neoplasms; Nanomedicine; Nanoparticles; Oxygen; Photochemotherapy; Photosensitizing Agents; Platinum; Porphyrins; Squamous Cell Carcinoma of Head and Neck | 2023 |
Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer.
Topics: Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Comparison of real-world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials.
Topics: Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Recurrence, Local; Platinum; Randomized Controlled Trials as Topic; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Analgesics, Opioid; Antibodies, Monoclonal; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Female; Head and Neck Neoplasms; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2023 |
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Topics: Carcinoma, Squamous Cell; Double-Blind Method; Head and Neck Neoplasms; Humans; Immunotherapy; Ipilimumab; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Topics: Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Predictors of early progression after curative resection followed by platinum-based adjuvant chemoradiotherapy in oral cavity squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease Progression; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis | 2021 |
Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Topics: Antibodies, Monoclonal, Humanized; China; Cost-Benefit Analysis; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Platinum; Quality-Adjusted Life Years; Squamous Cell Carcinoma of Head and Neck | 2020 |
A novel seven-gene panel predicts the sensitivity and prognosis of head and neck squamous cell carcinoma treated with platinum-based radio(chemo)therapy.
Topics: Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Platinum; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2021 |
A novel seven‑gene panel predicts prognosis of head and neck squamous cell carcinoma treated with platinum‑based radio(chemo)therapy.
Topics: Chemoradiotherapy; Head and Neck Neoplasms; Humans; Platinum; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2021 |
Author's reply to "A novel seven-gene panel predicts the sensitivity and prognosis of head and neck squamous cell carcinoma treated with platinum-based radio(chemo)therapy".
Topics: Head and Neck Neoplasms; Humans; Platinum; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2021 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Practice Patterns, Physicians'; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2019 |
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Adducts; DNA, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mutation; Platinum; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck; Statistics, Nonparametric; Tumor Suppressor Protein p53 | 2013 |
Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Risk Assessment; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2015 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Europe; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Grading; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Incidence; Japan; Male; Middle Aged; Mucositis; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2015 |
Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry.
Topics: Aged; Carcinoma, Squamous Cell; Cell Line, Tumor; Chromatography, Liquid; Cytostatic Agents; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Platinum; Reproducibility of Results; Squamous Cell Carcinoma of Head and Neck; Tandem Mass Spectrometry | 2012 |